Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes

References

• BaileyCJTurnerRC1996MetforminN Engl J Med33457498569826
   PubMed Web of Science ®Google Scholar
• BaronMA2003Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et alDiabetes Care263361214633839
   PubMedGoogle Scholar
• Centers for Disease Control and PreventionNational diabetes fact sheet: United States2005 [online]. Accessed September 11, 2007.URL: http://apps.nccd.cdc.gov/ddtstrs/template/ndfs_2005.pdf
   Google Scholar
• CerielloA2000The post-prandial state and cardiovascular disease: relevance to diabetes mellitusDiabetes Metab Res Rev161253210751752
   PubMed Web of Science ®Google Scholar
• CookMNGirmanCJSteinPP2007Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary careDiabet Med24350817335466
   PubMed Web of Science ®Google Scholar
• DeFronzoRA1999Pharmacologic therapy for type 2 diabetes mellitusAnn Intern Med13128130310454950
   PubMed Web of Science ®Google Scholar
• DeFronzoRAFerranniniESimonsonDC1989Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptakeMetabolism38387952657323
   PubMed Web of Science ®Google Scholar
• DeFronzoRAGoodmanAMMulticenter Metformin Study Group1995Efficacy of metformin in patients with non-insulin-dependent diabetes mellitusN Engl J Med33354197623902
   PubMed Web of Science ®Google Scholar
• DerosaGD’AngeloAFogariE2007Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trialIntern Med4618374618025765
   PubMed Web of Science ®Google Scholar
• FrenchJA2001The role of new antiepileptic drugsAm J Manag Care7S209S21411474769
   PubMed Web of Science ®Google Scholar
• GerichJRaskinPJean-LouisL2005PRESERVE-β: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metforminDiabetes Care282093916123472
   PubMed Web of Science ®Google Scholar
• HortonESClinkingbeardCGatlinM2000Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetesDiabetes Care231660511092289
   PubMed Web of Science ®Google Scholar
• HortonESFoleyJEShenSG2004Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetesCurr Med Res Opin20883915200747
   PubMed Web of Science ®Google Scholar
• KahnSE2003The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetesDiabetologia4631912637977
   PubMed Web of Science ®Google Scholar
• MainousAGIIIBakerRKoopmanRJ2007Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the wayDiabetologia509344017119914
   PubMed Web of Science ®Google Scholar
• MarreMVan GaalLUsadelK-H2002Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patientsDiabetes Obes Metab41778612047396
   PubMed Web of Science ®Google Scholar
• McLeodJF2004Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agentClin Pharmacokinet439712014748619
   PubMed Web of Science ®Google Scholar
• NarayanKMBoyleJPThompsonTJ2007Effect of BMI on lifetime risk for diabetes in the US Diabetes Care3015626
   PubMed Web of Science ®Google Scholar
• NataliAFerranniniE2006Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic reviewDiabetologia494344116477438
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMB2006Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia4917112116802130
   PubMed Web of Science ®Google Scholar
• PratleyREFoleyJEDunningBE2001Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose controlCurr Pharm Des713759711472274
   PubMed Web of Science ®Google Scholar
• QiaoQPyoralaKPyoralaM2002Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucoseEur Heart J2312677512175663
   PubMed Web of Science ®Google Scholar
• RaskinPKlaffLMcGillJ2003Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metforminDiabetes Care262063812832314
   PubMed Web of Science ®Google Scholar
• RisticSCollober-MaugeaisCCressierF2007Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial resultsDiabetes Obes Metab95061117587393
   PubMed Web of Science ®Google Scholar
• RisticSCollober-MaugeaisCPecherE2006Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin aloneDiabet Med237576216842480
   PubMed Web of Science ®Google Scholar
• RosenstockJHassmanDRMadderRD2004Repaglinide versus nateglinide monotherapy: a randomized, multicenter studyDiabetes Care2712657015161773
   PubMed Web of Science ®Google Scholar
• SchatzHSchoppelKLehwalderD2003Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditionsExp Clin Endocrinol Diabetes111262612951631
   PubMed Web of Science ®Google Scholar
• SchwarzSLGerichJEMarcellariA2008Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetesDiabetes Obes Metab106526017941876
   PubMed Web of Science ®Google Scholar
• WeaverJURobertsonDAtkinSL2004Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84Diabetes Obes Metab63445215287927
   PubMed Web of Science ®Google Scholar
• WeyerCBogardusCMottDM1999The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJ Clin Invest1047879410491414
   PubMed Web of Science ®Google Scholar
• WildSRoglicGGreenA2004Global prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care2710475315111519
   PubMed Web of Science ®Google Scholar